🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ganesan Vaidyanathan

Duke Medical Center

ORCID: 0000-0003-3041-8275

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent — N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate”.

Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent — N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate

Nuclear Medicine and Biology(2021)10.1016/j.nucmedbio.2021.06.002

N/A

0.312DataRank · unranked

7 citations

Darryl McDougald, Rebecca Meshaw, Irina V. Balyasnikova, Michael R. Zalutsky, Ganesan Vaidyanathan +1 more

Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer

Nuclear Medicine and Biology(2021)10.1016/j.nucmedbio.2021.01.002

N/A

0DataRank · unranked

30 citations

Ronnie C. Mease, Il Minn, Jae‐Yeon Choi, Ying Chen, Hassan M. Shallal +6 more

Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy

International Journal of Nanomedicine(2021)10.2147/ijn.s327577

N/A

0DataRank · unranked

28 citations

Zhengyuan Zhou, Yutian Feng, Xiaoguang Zhao, Ganesan Vaidyanathan, Michael R. Zalutsky +2 more

Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0400

N/A

0DataRank · unranked

31 citations

Minu Samanta, Mehran Makvandi, David Groff, Paul Martorano, Jimmy Elias +11 more

Low Level Whole-Brain Radiation Enhances Theranostic Potential Of Single Domain Antibody Fragments For HER2-Positive Brain Metastases

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.04.19.488555

N/A

0DataRank · unranked

0 citations

Stephen A. Jannetti, Μαρκέλλα Ζαννίκου, Zhengyuan Zhou, Darryl McDougald, Deepak Kanojia +4 more

Data from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

(2023)10.1158/1078-0432.c.6532614.v1

N/A

0DataRank · unranked

0 citations

Minu Samanta, Mehran Makvandi, David Groff, Paul Martorano, Jimmy Elias +11 more

Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative

Bioorganic & Medicinal Chemistry(2020)10.1016/j.bmc.2020.115634

N/A

0DataRank · unranked

23 citations

Michael R. Zalutsky, Ganesan Vaidyanathan, Zhengyuan Zhou

A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation

Nuclear Medicine and Biology(2024)10.1016/j.nucmedbio.2024.108916

N/A

0DataRank · unranked

16 citations

Rebecca Meshaw, S. W. Finch, Yongxiang Zheng, Il Minn, Ganesan Vaidyanathan +3 more